论文部分内容阅读
目的 探讨老年急性心肌梗死患者接受重组链激酶溶栓治疗的疗效和安全性。方法 2 5 5例急性心肌梗死患者分为老年组 (15 7例 )和非老年组 (98例 ) ,分别对两组的临床疗效进行比较。结果 非老年组与老年组比较 ,其梗死相关血管再通率 (81.6 %vs79.0 % )、梗死后心绞痛 (8.2 %vs7.6 % )、再梗死 (2 .0 %vs3.2 % )、严重心律失常(11.2 %vs10 .8% )、心源性休克 (5 .1%vs5 .1% )、出血 (2 3.5 %vs2 1.7% )及其他并发症的发生率均无显著性差异(P >0 .0 5 )。结论 老年急性心肌梗死接受重组链激酶溶栓治疗是安全、有效的。
Objective To investigate the efficacy and safety of thrombolytic therapy with recombinant streptokinase in elderly patients with acute myocardial infarction. Methods Twenty-five cases of acute myocardial infarction were divided into the elderly group (157 cases) and the non-elderly group (98 cases). The clinical efficacy of the two groups were compared. Results Compared with the elderly group, the rates of infarct-related revascularization (81.6% vs79.0%), post-infarction angina (8.2% vs7.6%), and recanalization (2.0% vs3.2% Serious arrhythmia (11.2% vs10.8%), cardiogenic shock (5.1% vs5.1%), bleeding (23.5% vs2 1.7%) and other complications were not significantly different (P > 0 .0 5). Conclusion Acute myocardial infarction in elderly patients receiving recombinant streptokinase thrombolysis is safe and effective.